Preoperative Planning With PSMA-PET in Melanoma Surgery Trial
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This is a non-randomised, single-centre Phase 2 study, investigating whether the diagnostic biomarker, prostate-specific membrane antigen (PSMA), can detect melanoma metastases using PSMA PET/ CT.
Eligibility
Participation Requirements
Sex: Male
Minimum Age: 18
Healthy Volunteers: f
View:
• Males ≥18 years of age
• Biopsy proven first and recurrent metastatic melanoma with palpable nodal disease who have undergone a staging FDG PET-CT scan as part of routine clinical care and are scheduled for surgery for resection of the primary site
Locations
Other Locations
United Kingdom
The Royal Marsden NHS Foundation Trust
RECRUITING
London
Contact Information
Primary
Reyhaneh Sadegh Zadeh
reyhaneh.sadeghzadeh@rmh.nhs.uk
020 7352 8171
Time Frame
Start Date: 2025-03-11
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 16
Treatments
Experimental: PSMA PET-CT
Within the two weeks prior to surgery, the patients will undergo both PSMA PET-CT \& FDG PET-CT scans at least 48 hours apart.~The Investigational Medicinal Product (IMP) under investigation in this trial is 68Ga-PSMA. This is an imaging radionuclide tracer.
Related Therapeutic Areas
Sponsors
Leads: Royal Marsden NHS Foundation Trust